TRPA1 and migraine disorder: However, the proposed therapeutic potential of TRPA1 in headache disorders is supported by the fact that sumatriptan, the iconic anti-migraine medicine, has been recently demonstrated to inhibit TRPA1-mediated vasodilation in meningeal tissues [56].